Dr. Adrian Barker is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm's patents and innovations practice. Adrian is a cellular and molecular biologist with over ten years of research experience in both academia and industry. He has a broad range of technical expertise in cell and molecular biology, developmental biology, cancer biology, biochemistry, and microfluidics. His practice involves patent prosecution and due diligence for clients in the life sciences, biotechnology, diagnostics, pharmaceuticals, and microfluidics.
Prior to joining the firm, Adrian worked in the legal group at Fluidigm Corporation, where he provided his scientific expertise to intellectual property matters and patent prosecution in microfluidics, next-generation sequencing, PCR, droplet-based technologies, and single-cell biology. He also worked at Pfizer, Inc., in the cell biology department researching pharmaceuticals for Type II diabetes.
Adrian's doctoral research at the University of California, San Francisco, focused on the regulation and maintenance of the epithelial barrier in mammals. Specifically, he studied signaling mechanisms involved in the initiation of epithelial cell extrusion, a phenomenon in which an apoptotic epithelial cell is removed from the barrier by neighboring cells. He also studied similar signaling pathways involved in closure of the neural tube during embryonic development.
Dr. Adrian Barker is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm's patents and innovations practice. Adrian is a cellular and molecular biologist with over ten years of research experience in both academia and industry. He has a broad range of technical expertise in cell and molecular biology, developmental biology, cancer biology, biochemistry, and microfluidics. His practice involves patent prosecution and due diligence for clients in the life sciences, biotechnology, diagnostics, pharmaceuticals, and microfluidics.
Prior to joining the firm, Adrian worked in the legal group at Fluidigm Corporation, where he provided his scientific expertise to intellectual property matters and patent prosecution in microfluidics, next-generation sequencing, PCR, droplet-based technologies, and single-cell biology. He also worked at Pfizer, Inc., in the cell biology department researching pharmaceuticals for Type II diabetes.
Adrian's doctoral research at the University of California, San Francisco, focused on the regulation and maintenance of the epithelial barrier in mammals. Specifically, he studied signaling mechanisms involved in the initiation of epithelial cell extrusion, a phenomenon in which an apoptotic epithelial cell is removed from the barrier by neighboring cells. He also studied similar signaling pathways involved in closure of the neural tube during embryonic development.